Pharmaceutical Technology
FEBRUARY 29, 2024
India’s Tata Institute has developed a tablet combining resveratrol and copper that has the potential to prevent the recurrence of cancer.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 29, 2024
Even small doses of LSD could have therapeutic benefits for mental health and task performance, a new study shows. Researchers from the US and Germany gave 21 adults either a placebo or 13 or 26 micrograms of LSD – small doses that rarely lead to hallucinatory effects.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 29, 2024
LUT014 is being investigated in an ongoing Phase II trial as a first-line treatment for EGFR inhibitor-induced acneiform rash, for which there is no approved drug.
Bio Pharma Dive
FEBRUARY 29, 2024
The unusual deal will see one of the investment firm’s startups work with Gilead to expand the cancer drug’s label, with Abingworth receiving payment if successful.
Pharmaceutical Technology
FEBRUARY 29, 2024
Amyotrophic lateral sclerosis (ALS) is a swiftly advancing, fatal neurodegenerative condition marked by muscle weakness, atrophy, and spasticity.
Bio Pharma Dive
FEBRUARY 29, 2024
The startup, Kenai Therapeutics, has raised $82 million and will be chaired by Jeff Jonas, a new Cure partner and former CEO of Sage Therapeutics.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 29, 2024
The Central Drugs Standard Control Organisation (CDSCO) has declared almost 5 per cent of the total drug samples it tested during the month of January, 2024 as Not of Standard Quality (NSQ). The number of samples tested, however, has declined during the month compared to the previous months.
Pharmaceutical Technology
FEBRUARY 29, 2024
The US HHS Secretary called for state collaboration on a project to improve gene therapy access for sickle cell disease.
Bio Pharma Dive
FEBRUARY 29, 2024
Less than two years after Bristol Myers bought Turning Point for $4.1 billion, Jean Cui and Peter Li have built a new startup that’s brought in more than $170 million in funding.
Pharmaceutical Technology
FEBRUARY 29, 2024
For Indena, the leading company dedicated to the identification, development and production of high-quality active principles derived from plants, custom services have been a key area of expertise for some time now.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
FEBRUARY 29, 2024
Explore how innovation in healthcare can be scaled across hospitals and nations, driving transformation through research & development, biotech collaborations, and fostering start-ups in the industry.
Pharmaceutical Technology
FEBRUARY 29, 2024
Research published by the British Medical Journal on 28 February 2024, has found that ultra-processed foods (UPFs), including cereals, chocolate bars, and ready meals, are linked to 32 negative health outcomes.
Antidote
FEBRUARY 29, 2024
Rare Disease Day, typically observed on February 28th, will be celebrated this year on February 29th! Rare Disease Day is an awareness holiday intended to generate change for the 300 million people who are diagnosed with a rare disease worldwide, as well as their families and caregivers.
Pharmaceutical Technology
FEBRUARY 29, 2024
Indena CDMO origin: Founded in 1921 by Carlo Boccaccio Inverni and Biagio Alberto Della Beffa and headquartered in Milan, Indena…
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Outsourcing Pharma
FEBRUARY 29, 2024
Yesterday, (February 28), a clinical-stage biotechnology company, Redx, announced that the first participant has been dosed in a phase 1 clinical trial for RXC008.
Pharmaceutical Technology
FEBRUARY 29, 2024
The UK MHRA has announced new process changes in its latest guidance for enhancing the efficiency of assessing established therapies.
Outsourcing Pharma
FEBRUARY 29, 2024
Lifebit, a progressive biomedical data technology and services company, has reached a huge milestone, boasting a catalog of 100 million patients in its multi-omic and health data repository.
Pharmaceutical Technology
FEBRUARY 29, 2024
An Eli Lilly-sponsored GlobalData report finds that obese workers had $6,472 higher annual in medical and economic costs.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Fierce Pharma
FEBRUARY 29, 2024
Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. | Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. But a new funding pact between Carlyle’s Abingworth and Gilead Sciences is somewhat unconventional.
Pharmaceutical Technology
FEBRUARY 29, 2024
Every Cure has received $48.3m contract from the ARPA-H, marking a significant federal investment in drug repurposing.
Pharma Times
FEBRUARY 29, 2024
Aphasia is a language disorder caused by some form of brain damage, including stroke
Pharmaceutical Technology
FEBRUARY 29, 2024
After a challenging few years post-pandemic, industry professionals believe diagnostic testing is back on track
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Fierce Pharma
FEBRUARY 29, 2024
For the second time in four weeks, GSK has settled a personal injury lawsuit in California sta | For the second time in four weeks, GSK has settled a personal injury lawsuit in California state court over the heartburn drug Zantac. The company revealed the dismissal of the case and the agreement in a release Thursday.
pharmaphorum
FEBRUARY 29, 2024
It’s been a couple of months since pharma’s annual JP Morgan Chase Healthcare Conference, where the mood around pharma M&A this year was optimistic, albeit with a few caveats. On today’s podcast, host Jonah Comstock is joined by Cody Powers, principal of portfolio and business development at ZS Associates, to discuss those trends and predictions and how they’re shaking out so far.
Fierce Pharma
FEBRUARY 29, 2024
As Johnson & Johnson's U.S. exclusivity period on its immunology blockbuster Stelara ticks away, another biosimilar player has lined up for the piece of the drug's sales pie. | As Johnson & Johnson's U.S. exclusivity period on Stelara ticks away, another biosimilar player has lined up for the piece of the blockbuster's sales pie.
pharmaphorum
FEBRUARY 29, 2024
Explore the impact of the Inflation Reduction Act (IRA) on drug prices and negotiations within the life sciences industry, as it stands on the threshold of change. Gain insights into the potential outcomes and implications of this legislation.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Reporter
FEBRUARY 29, 2024
Being able to identify rare diseases is a challenging aspect especially since more than 80% of them have genetic origins.
pharmaphorum
FEBRUARY 29, 2024
On Rare Disease Day, Clinigen has launched a campaign to try to encourage doctors and patients to explore how they can get early access to investigational therapies.
Fierce Pharma
FEBRUARY 29, 2024
Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract manufacturer has announced it’s being bought by one of its production peers | Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract manufacturer has announced it’s being bought by one of its production peers in Florida.
pharmaphorum
FEBRUARY 29, 2024
Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
358 
Let's personalize your content